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Several lines of evidence have shown
that the vasculature of each organ
expresses a unique set of functional mol-
ecules that dictate endothelial hetero-
geneity specific to that particular organ.
Similarly, tumor vasculature expresses
unique markers that distinguish it 
from normal vasculature. The question
of whether tumor vasculature during
carcinogenic progression has stage-spe-
cific molecular changes has not been
addressed. This is primarily due to a lack
of models or technology to identify such
transiently expressed surface proteins
during tumor progression. Two reports in
this issue of Cancer Cell have identified
unique molecular signatures that are
specifically expressed at different stages
of tumor progression from a highly
proliferative and angiogenic dysplastic
lesion to invasive phase by combining
phage display techniques with trans-
genic mice engineered to develop spon-
taneous tumors. They have identified a
set of phage peptide motifs that specifi-
cally home to the vasculature of either
dysplastic or invasive pancreatic and
squamous skin cancers. These studies
will most likely lay the foundation for
identifying unique therapeutic targets
that are selectively expressed on the
tumor vasculature.
What is unique about tumor vascula-
ture that provides a distinct platform for
selective phage peptide homing? Tumor
vessels are structurally and physiologi-
cally different than normal vasculature
(Carmeliet and Jain, 2000; Hanahan and
Folkman, 1996). Typical tumor vessels
are tortuous, leaky, and discontinuous,
and they are invested with disorganized
peri-endothelial supportive cells. The
determinant of tumor vasculature hetero-
geneity is dictated in part by dys-
regulated expression of tumor-derived
angiogenic factors, including VEGFs,
FGFs, PDGFs, as well as yet unrecognized
angiogenic factors. Overexpression of the
angiogenic factor, VEGF, results in gen-
eration of unstable, dilated, leaky
neovessels and induction of expression
of adhesion molecules promoting infiltra-
tion of inflammatory cells (Benjamin et
al., 1999; Bergers et al., 1999). Moreover,
recruitment of endothelial cells (ECs)
from local preexisting vasculature as well
as circulating marrow-derived endothe-
lial progenitors may provide for another
dimension of tumor vasculature hetero-
geniety (Rafii et al., 2002).
Identification of tumor stage-specific
endothelial markers has been hindered
in part by technical difficulties in isolating
pure population of functionally intact and
phenotypically stable populations of ECs
from various carcinogenic stages. In
addition, in vitro cultivation of purified
populations of ECs may lose their endur-
ing stage-specific traits. To circumvent
these problems, several groups have
used highly sophisticated molecular and
immunological approaches to identify
unique markers that are expressed on
the surface of tumor but not on normal
vasculature. Serial analysis of gene
expression (SAGE) is a mRNA profiling
technology in which clones of concate-
nated short sequence tags (10–17 bp)
derived from mRNA of targeted cells are
generated, sequenced, and analyzed
with a deconvolution algorithm (St. Croix
et al., 2000). The major strength of the
SAGE technique is its ability to quantify
global gene expression without prior
sequence information. SAGE has been
used to identify genes and ESTs that are
selectively expressed or upregulated in
the human colon cancer relative to
normal vasculature (St. Croix et al.,
2000). However, genes identified by 
SAGE analysis require additional time-
consuming and cumbersome develop-
ment of reagents to validate their tumor
vasculature specificity and functionality.
An alternative and complimentary
means to probe tumor vasculature that
allows for rapid identification of specific
markers involves in vivo phage display
technology. Phage display peptide
libraries contain peptide motifs that can
home to the tumor vasculature and 
bind directly to the molecules expressed 
on tumor vessels (Arap et al., 1998;
Pasqualini and Ruoslahti, 1996;
Ruoslahti, 2002). In vivo peptide phage
display screening technology has the
added advantage of identifying stage-
specific, functionally active, surface-
expressed proteins of the tumor
vasculature. In some circumstances,
peptides expressed on the phage may
also block the function of the proteins,
thereby providing critical information
about the angiogenic properties of the
targeted proteins.
Identification of unique molecular
signatures that are selectively expressed
in each stage of tumor vasculature from
dormant/dysplastic to invasive phase
has several important therapeutic and
diagnostic applications. Peptides that
target the premalignant dysplastic phase
of tumor vessels can be used diag-
nostically to localize early tumors and
possibly be used therapeutically in a
neoadjuvant or adjuvant setting to pre-
vent the angiogenic switch (Figure 1).
Functional blockade by such peptides
that home to invasive tumors will also
allow radiological localization of the
micrometastatic tumors and can be used
as antiangiogenic agent.
Screening by phage peptide libraries
can be performed either in vitro or in
vivo. Phage display libraries contain an
average collection of bacteriophage par-
ticles displaying random phage peptides
in as many as 109 permutations. By
exposing the vasculature to phage
libraries by systemic perfusion and/or to
isolated primary cells ex vivo, peptides
that selectively bind can be enriched
through repetitive cycles of binding and
amplification. This will allow for rapid
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Tumor vasculature address book: Identification of stage-specific
tumor vessel zip codes by phage display
Using in vivo phage display technology with murine tumorigenesis models, two reports have identified peptide motifs that
selectively home to distinct molecular vascular targets in a tumor type- and stage-specific manner (Hoffman et al., 2003
and Joyce et al., 2003 [this issue of Cancer Cell]). By probing the surface-protein repertoire of these unique vascular beds,
a pioneering draft of a molecular roadmap to decipher the heterogeneity of the vascular system in the context of carcino-
genic progression has been plotted. Analysis of these phage peptides that differentially home to dysplastic or invasive
tumor vasculature will lay the foundation for identifying unique functional tumor vascular-specific motifs that could poten-
tially be applied to targeted therapeutic and imaging modalities.
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identification of genes that are upregulat-
ed from normal to tumor blood vessels. A
number of published studies with phage
libraries have reported the identification
of vascular targeting receptors in
tumors, primarily in mice (Giordano et
al., 2001; Pasqualini and Ruoslahti, 1996;
Ruoslahti, 2002) and also in a patient
(Arap et al., 2002b). In vivo screening of
phage libraries in murine models has
identified specific motifs, including RGD,
GSL, and NGR, that bind to integrins
αvβ3, αvβ5, and α5β1, matrix metallo-
proteinases, and vascular growth factor
receptors that are upregulated in neoan-
giogenic tumor ECs (Pasqualini and
Arap, 2002; Pasqualini et al., 2002;
Ruoslahti, 2002). Using this technology,
IL11 receptor has been identified to be
selectively expressed in prostate vessels
(Arap et al., 2002a; Pasqualini and Arap,
2002), and the aminopeptidase P has
been shown to target breast tumor vas-
culature (Essler and Ruoslahti, 2002).
However, these studies did not provide
a temporal pattern of selective phage
homing during tumor progression from
premalignant to the invasive phase, and
homing of RGD, GSL, and NGR peptides
was independent of the origin of the
tumor.
In the current report by Hoffman et
al. (2003), a heptameric cyclic phage
(CX7C) peptide library was used to iden-
tify homing peptides that selectively bind
to the dysplastic and squamous carcino-
mas of K14-HPV16 transgenic mice.
One peptide that selectively homed to
the tumor endothelial cells was identical
to a sequence in the human kallikrein-9
protease. In the companion report using
a combined in vitro and in vivo phage
library, Joyce et al. (2003) demonstrate
that there exists specific surface protein
differences in the vasculature of pancre-
atic tumors in a RIP-Tag2 transgenic
mouse model of tumorigenesis. By
employing the aforementioned peptide
phage panning techniques, they probed
cells with access to the vasculature, in
particular, ECs, pericytes, and tumor
cells. Peptide motifs specific to normal,
premalignant and tumor vessels that
imply that the vasculature has a distinct
and specific progression in line with
tumor development were obtained. One
peptide homing to the tumor vessels was
found homologous to pro-PDGF-B.
Additionally, they detected differences in
the peptide binding profile between the
vasculature of a pancreatic islet tumor
and an ectopic implanted tumor, which
suggests a context-dependant molecular
signature for tumors. The finding that
pro-PDGF-B peptide was only detected
in the pancreatic tumors may be due to
the finding that as compared to skin
squamous cancers, RIP-Tag2 pancreatic
tumors are leaky and develop micro-
morrhages, therefore exposing these
peptides to PDGF receptor-positive peri-
cytic cells. Nonetheless, tumor vascular
leakiness is a unique feature of certain
tumors that may be exploited to target
specific peptides. By combining in vivo
phage display panning techniques with a
progressive genetic tumor model, these
groups have been able to track the
differential surface protein repertoire of
tumor vasculature in its progression from
dormant dysplasia to invasive metastatic
disease.
However, these two studies also
have few shortcomings. It is not clear
whether kallikrein-9 protease or pro-
PDGF-B play any significant physiologi-
cal role during tumor progression or just
serve as unique stage-specific vascular
molecular signatures. Moreover, there
are also the potential hurdles associated
with the translation of the data deri-
ved from mouse models to humans.
Particularly, stage-specific peptide probes
isolated in mouse tumor models may not
always be replicable in human tumors.
Indeed, the expression pattern of mole-
cules in human tumors may be drastical-
ly different from the RIP-Tag pancreatic
or the HPV16 skin carcinogenesis mod-
els. In addition, the degree of tumor vas-
cular leakiness and stabilization may
also differ significantly in tumors devel-
oping in murine models of tumorigeneiss
and de novo human cancers. Wound
healing and organ regeneration after tis-
sue ischemia requires formation of
neovessels, which may express a 
similar surface protein profile to tumor
vasculature. Therefore, it remains to be
determined whether any of the stage-
specific peptides will also home to the
neoangiogenic vessels during tissue
revascularization after ischemic damage.
It is possible that a certain subset of pep-
tide motifs may have selective activity for
tumor vessels and that some peptides
are inclusive of all newly formed vessels.
Nonetheless, identification of these known
and as of yet novel tumor vasculature-
specific peptides will provide a platform
for future studies to challenge the role of
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Figure 1. Homing of phage peptides to dis-
tinct molecular zip codes on endothelial
cell surface
Selective binding of these peptides corre-
lates with the progression of tumor in a
stage-specific manner. The homing peptides
EGRG and HGGVG differentially bind to
normal pancreas and skin vasculature,
respectively. In the K14-HPV16 squamous
tumorigenesis model, phage peptides CNR-
RTKAGC and CSRPRRSEC are specific for
dysplastic skin neovasculature while CDTRL
and CGKRK are selective for tumor neovas-
culature. In the RIP-Tag tumorigenesis model,
phage peptides CRSRKG and CEYQLDVE
target for angiogenic/dysplastic pancreatic
islets while CKAAKNA and CKGAKAR home
to pancreatic tumor neovasculature.
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these factors in the modulation of neoan-
giogenesis. In addition, it remains to be
determined whether these peptides,
such as dysplasia-specific homing pep-
tide CSRPRRSEC, play any significant
role in wound healing, tissue revascular-
ization after ischemia, or whether this
homing is a salient feature of tumors.
Taken together, these findings set
forth an enticing hypothesis of a func-
tional vascular heterogeneity that can be
studied and used in the future to under-
stand the underlying pathogenesis of
tumor neoangiogenic processes. This
approach will also provide for new
molecular targets for radiographic tumor
detection and molecularly directed
chemotherapeutic drug delivery and
drug sensitivity testing. Given the fidelity
in homing of these peptides to their vas-
cular targets, fusion of a specific peptide
with an antiangiogenic agent will facili-
tate delivery of high concentrations of a
toxin to disrupt tumor vessels. In light of
the unparalleled specificity of phage
peptides, there is no doubt that this tech-
nology will allow us to identify stage-spe-
cific tumor and organ-specific vascular
zip codes. This will facilitate identification
of therapeutic targets to block tumor
angiogenesis and inhibit angiogenic
switches with minimal toxicity to other tis-
sue organs, such as those during
postnatal development or physiologically
regenerative processes.
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Cancer has long been thought of as a
multistep process, involving cooperation
between several oncogenic events and
mutations in tumor suppressors to yield
full-blown cellular transformation and
metastasis (Hanahan and Weinberg,
2000). Drosophila possesses ideal tools
to study the clonal effects of multiple
genetic manipulations on populations of
cells alongside phenotypically normal
cells. However, its potential for studying
the stepwise nature of the transformation
process had so far been largely untapped.
This looks set to change with the publi-
cation of two complementary reports by
the laboratories of Tian Xu and Helena
Richardson focusing on cooperation
between multiple genetic events to pro-
mote neoplastic growth and metastasis
(Brumby and Richarson, 2003; Pagliarini
and Xu, 2003).
These studies were facilitated by the
use of the MARCM technique (Lee and
Luo, 2001). Importantly, the MARCM
technique allows the generation, in a
heterozygous animal, of clones of cells
that (1) are homozygous mutant for vari-
ous mutations, (2) overexpress a trans-
gene(s) of interest, and (3) are labeled
positively with a GFP marker. Thus, the
MARCM technique is a versatile tool with
which the consequences of multiple
genetic manipulations upon positively
marked cells can be examined in vivo. In
both studies, the formation of these
clones was targeted to the eye imaginal
disc.
A model for metastasis in Drosophila
The Ras protooncogene is activated in
about 30% of human cancers (Hanahan
and Weinberg, 2000). Ras has been
implicated in the metastatic process in
mammalian systems, though its precise
in vivo contribution is not fully under-
Modeling transformation and metastasis in Drosophila
Transformation and metastasis are complex, multistep processes.Two recent papers exploit powerful Drosophila genetics
techniques to explore cooperation between multiple genetic manipulations and to model these processes. In particular,
oncogenic Ras is found to collaborate with disruption of cell polarity to trigger massive neoplasia and metastasis. These
studies promise further progress in research into the causes of cancer.
